Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 5 , Pages 543-554 , October 2009

The epidemiology and genetics of pituitary adenomas

References 

  1. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101(3):613–619
  2. Costello RT. Subclinical adenoma of the pituitary gland. American Journal of Pathology. 1936;12(2):205–216
  3. Vernooij MW, Ikram MA, Tanghe HL, et al. Incidental findings on brain MRI in the general population. New England Journal of Medicine. 2007;357(18):1821–1828
  4. Kim JH, Seo JSLBW, Lee SY, et al. The characteristics of incidental pituitary microadenomas in 120 Korean forensic autopsy cases. Journal of Korean Medical Science. 2007;22(Suppl.):S61–S65
  5. Buurman H, Saeger W. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. European Journal of Endocrinology. 2006;154(5):753–758
  6. Central Brain Tumor Registry of the United States 2007–2008 statistical report. 2008.
  7. Davis FG, Kupelian V, Freels S, et al. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro-oncology. 2001;3(3):152–158
  8. Finnish Cancer Registry . Cancer in Finland 2005–2006. Cancer Society of Finland; 2006;
  9. Clayton RN. Sporadic pituitary adenomas: from epidemiology to use of databases. Baillière's Best Practice & Research Clinical Endocrinology & Metabolism. 1999;13(3):451–460
  10. Ambrosi B, Faglia G. Epidemiology of pituitary tumors. In:  Faglia G,  Beck-Peccoz P,  Ambrosi B editor. Pituitary adenomas: new trends in basic and clinical research. Amsterdam: Elsevier; 1991;p. 159–168
  11. Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4769–4775
  12. Schneider HJ, Sievers C, Saller B, et al. High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clinical Endocrinology. 2008;69(3):432–435
  13. Landis CA, Masters SB, Spada A, et al. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature. 1989;340(6236):692–696
  14. Hayward BE, Barlier A, Korbonits M, et al. Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly. Journal of Clinical Investigation. 2001;107(6):R31–R36
  15. Scheithauer BW, Laws EJ, Kovacs K, et al. Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Seminars in Diagnostic Pathology. 1987;4(3):205–211
  16. Erdheim J. Zur normalen und pathologischen Histologie der Glandula thyreoidea, parathyroidea und Hypophysis. Beiträge zur pathologischen Anatomie und zur allgemeinen Pathologie. 1903;33:158–165
  17. Wermer P. Genetic aspects of adenomatosis of endocrine glands. American Journal of Medicine. 1954;16(3):363–371
  18. Larsson C, Skogseid B, Oberg K, et al. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature. 1988;332(6159):85–87
  19. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276(5311):404–407
  20. Fromaget M, Vercherat C, Zhang C, et al. Functional characterization of a promoter region in the human MEN1 tumor suppressor gene. Journal of Molecular Biology. 2003;333(1):87–102
  21. Sayo Y, Murao K, Imachi H, et al. The multiple endocrine neoplasia type 1 gene product, menin, inhibits insulin production in rat insulinoma cells. Endocrinology. 2002;143(6):2437–2440
  22. La P, Schnepp RW, Petersen D, et al. Tumor suppressor menin regulates expression of insulin-like growth factor binding protein 2. Endocrinology. 2004;145(7):3443–3450
  23. Namihira H, Sato M, Murao K, et al. The multiple endocrine neoplasia type 1 gene product, menin, inhibits the human prolactin promoter activity. Journal of Molecular Endocrinology. 2002;29(3):297–304
  24. Lemos M, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Human Mutation. 2008;29(1):22–32
  25. Hai N, Aoki N, Shlmatsu A, et al. Clinical features of multiple endocrine neoplasia type 1 (MEN1) phenocopy without germline MEN1 gene mutations: analysis of 20 Japanese sporadic cases with MEN1. Clinical Endocrinology. 2000;52(4):509–518
  26. Burgess JR, Nord B, David R, et al. Phenotype and phenocopy: the relationship between genotype and clinical phenotype in a single large family with multiple endocrine neoplasia type 1 (MEN 1). Clinical Endocrinology. 2000;53(2):205–211
  27. Scacheri PC, Davis S, Odom DT, et al. Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genetics. 2006;2(4):e51
  28. Agarwal SK, Impey S, McWeeney S, et al. Distribution of menin-occupied regions in chromatin specifies a broad role of menin in transcriptional regulation. Neoplasia. 2007;9(2):101–107
  29. Poisson A, Zablewska B, Gaudray P. Menin interacting proteins as clues toward the understanding of multiple endocrine neoplasia type 1. Cancer Letters. 2003;189(1):1–10
  30. Agarwal SK, Novotny EA, Crabtree JS, et al. Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(19):10770–10775
  31. Heppner C, Bilimoria K, Agarwal SK, et al. The tumor suppressor protein menin interacts with NFk-B proteins and inhibits NFk-B-mediated transactivation. Oncogene. 2001;20(36):4917–4925
  32. Kaji H, Canaff L, Lebrun JJ, et al. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(7):3837–3842
  33. La P, Silva AC, Hou Z, et al. Direct binding of DNA by tumor suppressor menin. Journal of Biological Chemistry. 2004;279(47):49045–49054
  34. Schnepp RW, Hou Z, Wang H, et al. Functional interaction between tumor suppressor menin and activator of S-phase kinase. Cancer Research. 2004;64(18):6791–6796
  35. Schnepp RW, Mao H, Sykes SM, et al. Menin induces apoptosis in murine embryonic fibroblasts. Journal of Biological Chemistry. 2004;279(11):10685–10691
  36. Skogseid B, Eriksson B, Lundqvist G, et al. Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. Journal of Clinical Endocrinology and Metabolism. 1991;73:281
  37. Burgess JR, Shepherd JJ, Parameswaran V, et al. Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. Journal of Clinical Endocrinology and Metabolism. 1996;81(7):2642–2646
  38. Marx S, Spiegel AM, Skarulis MC, et al. Multiple endocrine neoplasia type 1: clinical and genetic topics. Annals of Internal Medicine. 1998;129(6):484–494
  39. Verges B, Boureille F, Goudet P, et al. Pituitary disease in MEN Type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. Journal of Clinical Endocrinology and Metabolism. 2002;87(2):457–465
  40. Beckers A, Betea D, Valdes-Socin H, et al. The treatment of sporadic versus MEN1-related pituitary adenomas. Journal of Internal Medicine. 2003;253(6):599–605
  41. Zhuang Z, Vortmeyer AO, Pack S, et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Research. 1997;57(21):4682–4686
  42. Heppner C, Kester MB, Agarwal SK, et al. Somatic mutation of the MEN1 gene in parathyroid tumours. Nature Genetics. 1997;16(4):375–378
  43. Zhuang Z, Ezzat SZ, Vortmeyer AO, et al. Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Research. 1997;57(24):5446–5451
  44. Poncin J, Stevenaert A, Beckers A. Somatic MEN1 gene mutation does not contribute significantly to sporadic pituitary tumorigenesis. European Journal of Endocrinology. 1999;140(6):573–576
  45. Schmidt M, Henke R, Stangk A, et al. Analysis of the MEN1 gene in sporadic pituitary adenomas. Journal of Pathology. 1999;188(2):168–173
  46. Wenbin C, Asai A, Teramoto A, et al. Mutations of the MEN1 tumor suppressor gene in sporadic pituitary tumors. Cancer Letters. 1999;142(1):43–47
  47. Prezant TR, Levine J, Melmed S. Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors. Journal of Clinical Endocrinology and Metabolism. 1998;83(4):1388–1391
  48. Boggild MD, Jenkinson S, Pistorello M, et al. Molecular genetic studies of sporadic pituitary tumors. Journal of Clinical Endocrinology and Metabolism. 1994;78(2):387–392
  49. Asa SL, Somers K, Ezzat S. The MEN-1 gene is rarely down-regulated in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism. 1998;83(9):3210–3212
  50. Farrell WE, Simpson DJ, Bicknell J, et al. Sequence analysis and transcript expression of the MEN1 gene in sporadic pituitary tumours. British Journal of Cancer. 1999;80(1–2):44–50
  51. Theodoropoulou M, Cavallari I, Barzon L, et al. Differential expression of menin in sporadic pituitary adenomas. Endocrine Related Cancer. 2004;11(2):333–344
  52. Poncin J, Abs R, Bonduelle M, et al. Mutation analysis of the MEN1 gene in Belgian patients with multiple endocrine neoplasia type 1 and related diseases. Human Mutation. 1999;13(1):54–60
  53. Beckers A, Abs R, Reyniers E, et al. Variable regions of chromosome 11 loss in different pathological tissues of a patient with the multiple endocrine neoplasia type I syndrome. Journal of Clinical Endocrinology and Metabolism. 1994;79(5):1498–1502
  54. Farid N, Buehler S, Russell N, et al. Prolactinomas in familial multiple endocrine neoplasia syndrome type I. Relationship to HLA and carcinoid tumors. American Journal of Medicine. 1980;69(6):874–880
  55. Olufemi SE, Green J, Manickam P, et al. Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland. Human Mutation. 1998;11(4):264–269
  56. Fritz A, Walch A, Piotrowska K, et al. Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Research. 2002;62(11):3048–3051
  57. Piotrowska K, Pellegata NS, Rosemann M, et al. Mapping of a novel MEN-like syndrome locus to rat chromosome 4. Mammalian Genome. 2004;15(2):135–141
  58. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(42):15558–15563
  59. Georgitsi M, Raitila A, Karhu A, et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. Journal of Clinical Endocrinology and Metabolism. 2007;92(8):3321–3325
  60. Igreja SC, Chahal HS, Akker SA, et al. Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and AIP (aryl hydrocarbon receptor-interacting protein) genes in MEN1 syndrome patients without any detectable MEN1gene mutations. Clinical Endocrinology. 2009;70(2):259–264
  61. Leontiou CA, Gueorguiev M, van der Spuy J, et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. Journal of Clinical Endocrinology and Metabolism. 2008;93(6):2390–2401
  62. Ozawa A, Agarwal SK, Mateo CM, et al. The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. Journal of Clinical Endocrinology and Metabolism. 2007;92(5):1948–1951
  63. Carney JA, Hruska L, Beauchamp G, et al. Dominant inheritance of the complex of myxomas, spotty pigmentation and endocrine overactivity. Mayo Clinic Proceedings. 1985;61:165–172
  64. Boikos S, Stratakis CA. Carney complex: the first 20 years. Current Opinion in Oncology. 2007;19:24–29
  65. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the carney complex: diagnostic criteria and recommendations for patient evaluation. Journal of Clinical Endocrinology and Metabolism. 2001;86(9):4041–4046
  66. Casey M, Mah C, Merliss AD, et al. Identification of a novel genetic locus for familial cardiac myxomas and carney complex. Circulation. 1998;98(23):2560–2566
  67. Stratakis CA, Carney JA, Lin JP, et al. Carney complex, a familial multiple endocrine neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. Journal Clinical Investigation. 1996;97:699–705
  68. Veugelers M, Wilkes D, Burton K, et al. Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(39):14222–14227
  69. Kirschner LS, Sandrini F, Monbo J, et al. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex. Human Molecular Genetics. 2000;9(20):3037–3046
  70. Bossis I, Stratakis CA. Minireview: PRKAR1A: normal and abnormal functions. Endocrinology. 2004;145(12):5452–5458
  71. Stergiopoulos SG, Stratakis CA. Human tumors associated with Carney complex and germline PPKAR1A mutations: a protein kinase a disease!. FEBS Letters. 2003;546:59–64
  72. Pack SD, Kirschner LS, Pak E, et al. Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the “complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas” (Carney complex). Journal of Clinical Endocrinology and Metabolism. 2000;85(10):3860–3865
  73. Kurtkaya-Yapicier O, Scheithauer BW, Carney JA, et al. Pituitary adenoma in Carney complex: an immunohistochemical, ultrastructural, and immunoelectron microscopic study. Ultrastructural Pathology. 2002;26(6):345–353
  74. Kaltsas GA, Kola B, Borboli N, et al. Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours. Clinical Endocrinology. 2002;57(4):443–448
  75. Sandrini F, Kirschner LS, Bei T, et al. PRKAR1A, one of the Carney complex genes, and its locus (17q22-24) are rarely altered in pituitary tumours outside the Carney complex. Journal of Medical Genetics. 2002;39(12):e78
  76. Verloes A, Stevenaert A, Teh BT, et al. Familial acromegaly: case report and review of the literature. Pituitary. 1999;1(3):273–277
  77. Valdes-Socin H, Poncin J, Stevens V, et al. Adenomes hypophysaires familiaux isoles non lies avec la mutation somatique NEM-1. Suivi de 27 patients. Annales d'endocrinologie. 2000;61:301
  78. Valdes-Socin H, Betea D, Stevens V, et al. Familial isolated pituitary adenomas not related to the MEN-1 syndrome: A study of 27 patients. In:10th Meeting of the Belgian Endocrine Society 2000.
  79. Valdes-Socin H, Jaffrain-Rea ML, Tamburrano G, et al. Familial isolated pituitary tumors: clinical and molecular studies in 80 patients. The EndocrineSociety's 84th Annual Meeting, 2002; P3-663:647.
  80. Beckers A, Daly AF. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. European Journal of Endocrinology. 2007;157(4):371–382
  81. Villa C, Magri F, Morbini P, et al. Silent familial isolated pituitary adenomas: histopathological and clinical case report. Endocrine Pathology. 2008;19(1):40–46
  82. Daly AF, Jaffrain-Rea ML, Ciccarelli A, et al. Clinical characterization of familial isolated pituitary adenomas. Journal of Clinical Endocrinology and Metabolism. 2006;91(9):3316–3323
  83. Ciccarelli A, Daly A, Beckers A. The epidemiology of prolactinomas. Pituitary. 2005;8(1):3–6
  84. Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006;312(5777):1228–1230
  85. Daly AF, Vanbellinghen JF, Khoo SK, et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. Journal of Clinical Endocrinology and Metabolism. 2007;92(5):1891–1896
  86. Iwata T, Yamada S, Mizusawa N, et al. The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. Clinical Endocrinology. 2007;66(4):499–502
  87. Toledo RA, Lourenco DM, Liberman B, et al. Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma. Journal of Clinical Endocrinology and Metabolism. 2007;92(5):1934–1937
  88. Yu R, Bonert V, Saporta I, et al. Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):5126–5129
  89. Barlier A, Vanbellinghen JF, Daly AF, et al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. Journal of Clinical Endocrinology and Metabolism. 2007;92(5):1952–1955
  90. Georgitsi M, Raitila A, Karhu A, et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(10):4101–4105
  91. Georgitsi M, Karhu A, Winqvist R, et al. Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. British Journal of Cancer. 2007;96(2):352–356
  92. Petrulis J, Perdew G. The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chemico-biological Interactions. 2002;141(1–2):25–40
  93. Bell DR, Poland A. Binding of aryl hydrocarbon receptor (AhR) to AhR-interacting protein. The role of hsp90. Journal of Biological Chemistry. 2000;275(46):36407–36414
  94. Meyer BK, Perdew GH. Characterization of the AhR-hsp90-XAP2 core complex and the role of the immunophilin-related protein XAP2 in AhR stabilization. Biochemistry. 1999;38(28):8907–8917
  95. Meyer B, Petrulis J, Perdew GH. Aryl hydrocarbon (Ah) receptor levels are selectively modulated by hsp90-associated immunophilin homolog XAP2. Cell Stress Chaperones. 2000;5(3):243–254
  96. Carver LA, LaPres JJ, Jain S, et al. Characterization of the Ah Receptor-associated Protein, ARA9. Journal of Biological Chemistry. 1998;273(50):33580–33587
  97. Bolger GB, Peden AH, Steele MR, et al. Attenuation of the Activity of the cAMP-specific Phosphodiesterase PDE4A5 by Interaction with the Immunophilin XAP2. Journal of Biological Chemistry. 2003;278(35):33351–33363
  98. de Oliveira SK, Hoffmeister M, Gambaryan S, et al. Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor. Journal of Biological Chemistry. 2007;282(18):13656–13663
  99. Lin BC, Sullivan R, Lee Y, et al. Deletion of the aryl hydrocarbon receptor-associated protein 9 leads to cardiac malformation and embryonic lethality. Journal of Biological Chemistry. 2007;282(49):35924–35932
  100. Lin BC, Nguyen LP, Walisser JA, et al. A hypomorphic allele of aryl hydrocarbon receptor-associated protein-9 produces a phenocopy of the ahr-null mouse. Molecular Pharmacology. 2008;74(5):1367–1371
  101. Naves LA, Daly AF, Vanbellinghen JF, et al. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. European Journal of Endocrinology. 2007;157(4):383–391

PII: S1521-690X(09)00056-6

doi: 10.1016/j.beem.2009.05.008

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 5 , Pages 543-554 , October 2009

Article Tools